Evidence map›Paper›PMID 27898683›Full record

Trial reportPloS one2016

Mortality in HIV-Infected Alcohol and Drug Users in St. Petersburg, Russia.

Nadia S Fairbairn, Alexander Y Walley, Debbie M Cheng, Emily Quinn, Carly Bridden, Christine Chaisson, Elena Blokhina, Dmitry Lioznov, Evgeny Krupitsky, Anita Raj and 1 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 3 countries.

Nadia S FairbairnDepartment of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Alexander Y WalleyDepartment of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education Unit, Boston University School of Medicine/Boston Medical Center, Boston, Massachusetts, United States of America.
Debbie M ChengDepartment of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America.
Emily QuinnData Coordinating Center, Boston University School of Public Health, Boston, Massachusetts, United States of America.
Carly BriddenDepartment of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education Unit, Boston Medical Center, Boston, Massachusetts, United States of America.
Christine ChaissonData Coordinating Center, Boston University School of Public Health, Boston, Massachusetts, United States of America.
Elena BlokhinaFirst Pavlov State Medical University, St. Petersburg, Russian Federation.
Dmitry LioznovFirst Pavlov State Medical University, St. Petersburg, Russian Federation.
Evgeny KrupitskyFirst Pavlov State Medical University, St. Petersburg, Russian Federation.
Anita RajDivision of Global Public Health, University of California San Diego School of Medicine, La Jolla, California, United States of America.
Jeffrey H SametDepartment of Medicine, Section of General Internal Medicine, Clinical Addiction Research and Education Unit, Boston University School of Medicine/Boston Medical Center, Boston, Massachusetts, United States of America.
Boston Medical Center · USBoston University · USFirst Pavlov State Medical University of St. Petersburg · RUSt.Petersburg V.M.Bekhterev Psychoneurological Research Institute · RUUniversity of British Columbia · CAUniversity of California San Diego · US

Funding

Clinical Addiction Research and Education ProgramR25DA013582 · NIDA · BOSTON MEDICAL CENTER · PI JEFFREY H. SAMET, Alexander Yale Walley · 2001 to 2026
$8.9M
Advancing Clinical Research Training within Addiction Residency ProgramsR25DA033211 · NIDA · BOSTON MEDICAL CENTER · PI Patrick O'Connor, JEFFREY H. SAMET · 2012 to 2026
$4.2M
URBAN ARCH (2/5) Biostatistics and Data Management Core (BDM)U24AA020779 · NIAAA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CHENG, DEBBIE M. · 2011 to 2020
$3.6M
Mentoring the next generation of addiction clinician scientists while responding to the opioid epidemicR25DA037756 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI FAIRBAIRN, NADIA · 2014 to 2023
$3.6M
URBAN ARCH (1/5) Administrative Coordinating Core (Admin Core)U24AA020778 · NIAAA · BOSTON MEDICAL CENTER · PI SAMET, JEFFREY H. · 2011 to 2020
$3.5M
Maximizing Opportunity - HIV Prevention in Hospitalized Russian DrinkersR01AA016059 · NIAAA · BOSTON MEDICAL CENTER · PI SAMET, JEFFREY H. · 2006 to 2010
$3.2M
NIAAA NIH HHS R01 AA016059NIAAA NIH HHS U24 AA020778NIAAA NIH HHS U24 AA020779NIDA NIH HHS R25 DA013582NIDA NIH HHS R25 DA033211NIDA NIH HHS R25 DA037756
6 · The paper itself

Abstract

In Russia, up to half of premature deaths are attributed to hazardous drinking. The respective roles of alcohol and drug use in premature death among people with HIV in Russia have not been described. Criminalization and stigmatization of substance use in Russia may also contribute to mortality. We explored whether alcohol, drug use and risk environment factors are associated with short-term mortality in HIV-infected Russians who use substances. Secondary analyses were conducted using prospective data collected at baseline, 6 and 12-months from HIV-infected people who use substances recruited between 2007-2010 from addiction and HIV care settings in a single urban setting of St. Petersburg, Russia. We used Cox proportional hazards models to explore associations between 30-day alcohol hazardous drinking, injection drug use, polysubstance use and environmental risk exposures (i.e. past incarceration, police involvement, selling sex, and HIV stigma) with mortality. Among 700 participants, 59% were male and the mean age was 30 years. There were 40 deaths after a median follow-up of 12 months (crude mortality rate 5.9 per 100 person-years). In adjusted analyses, 30-day NIAAA hazardous drinking was significantly associated with mortality compared to no drinking [adjusted Hazard Ratio (aHR) 2.60, 95% Confidence Interval (CI): 1.24-5.44] but moderate drinking was not (aHR 0.95, 95% CI: 0.35-2.59). No other factors were significantly associated with mortality. The high rates of short-term mortality and the strong association with hazardous drinking suggest a need to integrate evidence-based alcohol interventions into treatment strategies for HIV-infected Russians.

Indexed as

Drug UsersAdultAlcohol-Related DisordersFemaleHIV InfectionsHumansMaleRussiaSocial Stigma

Identifiers

PMID27898683
PMCPMC5127495
OpenAlexW2557409325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.